ArticleJournal of travel medicine2025
Acute schistosomiasis in travellers: outcomes of a short-course therapy.
Article in Journal of travel medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Acute Schistosomiasis in a Traveler Returning From St. Croix, United States Virgin Islands: A Case Report.Cureus · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTherapy of acute schistosomiasis in travellers currently relies on poorly consistent combinations of corticosteroids and praziquantel. In a cluster of travellers recently infected with Schistosoma mattheei × Schistosoma haematobium hybrids during a trip to South Africa in 2017, we evaluated the safety and efficacy of short methylprednisolone cycles to suppress early symptoms and of a single-day praziquantel/methylprednisolone administration at well-defined time lapses.
methodsSymptomatic patients seen during the early phase, 4 to 5 weeks (week 4-5) after infection, were given oral methylprednisolone 0.5 mg/kg once daily in one or more cycles of three consecutive days until symptoms abated. Patients were seen again at week 7-8 to be given praziquantel 40 mg/kg in two divided doses 2 hours apart, followed by a single dose of oral methylprednisolone 0.5 mg/kg 2 hours later to prevent symptom exacerbation. All patients were reevaluated for symptoms and infection at week 12-14, using serum circulating anodic antigen (CAA) as a marker of active infection.
resultsA total of 34 infected individuals were longitudinally followed up. Of these, 21 patients with symptoms at presentation (week 4-5) were given methylprednisolone. Symptoms abated during the first three-day cycle in 15/21 (71%), during the second cycle in another 4/21 (19%), and during the third cycle in the remaining 2/21 (10%). All 34 participants were treated with the praziquantel/steroid combination at week 7-8; 9 (26%) had mild symptoms of short duration. Only 4 (12%) developed fever and needed 1 or 2 additional days of steroids. At week 12-14, serum CAA remained detectable in only one of the 34 participants.
conclusionIn most patients, a single three-day course of methylprednisolone was sufficient to suppress symptoms of acute schistosomiasis. Only few patients experienced short lived symptom exacerbation after taking a single-day praziquantel and methylprednisolone combination at 7-8 weeks following exposure. Infection was cleared in almost all cases 4-6 weeks later.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.